JP2020023549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020023549A5 JP2020023549A5 JP2019191044A JP2019191044A JP2020023549A5 JP 2020023549 A5 JP2020023549 A5 JP 2020023549A5 JP 2019191044 A JP2019191044 A JP 2019191044A JP 2019191044 A JP2019191044 A JP 2019191044A JP 2020023549 A5 JP2020023549 A5 JP 2020023549A5
- Authority
- JP
- Japan
- Prior art keywords
- naca
- therapeutic
- prophylactic agent
- agent according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 230000000069 prophylactic effect Effects 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 229960001563 acetylcysteine amide Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 230000004297 night vision Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021147283A JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076594P | 2014-11-07 | 2014-11-07 | |
| US62/076,594 | 2014-11-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Division JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147283A Division JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Division JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020023549A JP2020023549A (ja) | 2020-02-13 |
| JP2020023549A5 true JP2020023549A5 (enExample) | 2020-08-06 |
Family
ID=55909913
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12472157B2 (enExample) |
| EP (2) | EP3214934A4 (enExample) |
| JP (5) | JP2017533969A (enExample) |
| KR (3) | KR20230152177A (enExample) |
| CN (2) | CN108498495A (enExample) |
| AU (4) | AU2015342831B2 (enExample) |
| BR (1) | BR112017009584A2 (enExample) |
| CA (1) | CA2967327C (enExample) |
| HK (1) | HK1252822A1 (enExample) |
| RU (1) | RU2711913C2 (enExample) |
| WO (2) | WO2016073829A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| AU2015342831B2 (en) | 2014-11-07 | 2019-09-12 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with N-acetylcysteine amide |
| JP6849867B2 (ja) | 2014-11-11 | 2021-03-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 眼疾患を有する対象の治療に有用なバイオマーカー |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| AU2018338103B2 (en) | 2017-09-20 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US20190135741A1 (en) * | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| JP2021531340A (ja) * | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのｐｒｃ２サブユニットの阻害 |
| CN109096161B (zh) * | 2018-08-24 | 2020-10-27 | 武汉远大弘元股份有限公司 | 一种n-乙酰半胱氨酸的制备方法 |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| US12245998B2 (en) | 2019-01-11 | 2025-03-11 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis |
| KR102745520B1 (ko) | 2019-01-11 | 2024-12-23 | 나쿠이티 파마슈티컬스, 인코포레이티드 | 방사선 피부염을 방지 및 치료하고 피부 라이트닝 또는 피부 화이트닝을 위한 n-아세틸시스테인 아미드(naca) 및 (2r,2r')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(dinaca) |
| US11766413B2 (en) | 2019-01-11 | 2023-09-26 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) |
| CN115151251A (zh) * | 2020-01-24 | 2022-10-04 | 纳崔泰制药有限公司 | 用于治疗氧化应激的疾病和损伤的前药 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3252866A (en) | 1965-06-28 | 1966-05-24 | Mead Johnson & Co | 2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| WO2002100293A2 (en) | 2001-06-13 | 2002-12-19 | Webb-Waring Institute For Biomedical Research | A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same |
| BE1014949A3 (fr) | 2001-08-14 | 2004-07-06 | Probiox | Procede de detection de stress oxydant et trousse pour sa mise en oeuvre. |
| AU2003247144B2 (en) | 2002-08-02 | 2007-11-29 | Mor Research Applications Ltd. | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| EP1551399A4 (en) | 2002-09-30 | 2011-01-05 | Mark A Babizhayev | METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT |
| JP2005350405A (ja) | 2004-06-11 | 2005-12-22 | Shiseido Co Ltd | 重合抑制剤および即時型黒化防止用皮膚外用剤 |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| US20090234011A1 (en) | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| CN101232877A (zh) * | 2005-04-21 | 2008-07-30 | 格伦·A·戈尔茨坦 | 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺） |
| JP4840804B2 (ja) | 2006-01-20 | 2011-12-21 | 学校法人慶應義塾 | 酸化ストレスの判定方法 |
| WO2010048716A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US20120150029A1 (en) | 2008-12-19 | 2012-06-14 | University Of Miami | System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography |
| US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
| WO2011044230A2 (en) | 2009-10-06 | 2011-04-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions |
| EP2397125A1 (en) | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Antioxidant composition |
| US20120142550A1 (en) | 2010-12-06 | 2012-06-07 | Zehnder James L | Vanin 1 as a Peripheral Blood Oxidative Stress Sensor |
| WO2013138744A1 (en) | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| US20150148423A1 (en) * | 2012-04-26 | 2015-05-28 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| US20130303436A1 (en) | 2012-12-06 | 2013-11-14 | Stealth Peptides Internatioanl, Inc. | Peptide therapeutics and methods for using same |
| US20150328337A1 (en) | 2012-12-19 | 2015-11-19 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
| EP3122342B1 (en) | 2014-03-28 | 2020-09-23 | NaCuity Pharmaceuticals, Inc. | Method for the preparation of n-acetyl cysteine amide |
| AU2015342831B2 (en) | 2014-11-07 | 2019-09-12 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with N-acetylcysteine amide |
| JP6849867B2 (ja) | 2014-11-11 | 2021-03-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 眼疾患を有する対象の治療に有用なバイオマーカー |
| AU2017235631B2 (en) | 2016-03-17 | 2023-03-02 | Thiogenesis Therapeutics, Inc. | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders |
| CA3076392A1 (en) | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | Methods for the treatment of cysteamine sensitive disorders |
| AU2018338103B2 (en) | 2017-09-20 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| WO2019060704A1 (en) | 2017-09-22 | 2019-03-28 | University Of Florida Research Foundation | DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| GB2581656A (en) | 2017-11-17 | 2020-08-26 | Piraee Mahmood | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders |
| US20190151271A1 (en) | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CN108618993B (zh) | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
| WO2020102810A1 (en) | 2018-11-16 | 2020-05-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive gel eye drop for ocular delivery of cysteamine |
| US12245998B2 (en) | 2019-01-11 | 2025-03-11 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis |
| KR102745520B1 (ko) | 2019-01-11 | 2024-12-23 | 나쿠이티 파마슈티컬스, 인코포레이티드 | 방사선 피부염을 방지 및 치료하고 피부 라이트닝 또는 피부 화이트닝을 위한 n-아세틸시스테인 아미드(naca) 및 (2r,2r')-3,3'-디설판디일 비스(2-아세트아미도프로판아미드)(dinaca) |
| US11766413B2 (en) | 2019-01-11 | 2023-09-26 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) |
-
2015
- 2015-11-06 AU AU2015342831A patent/AU2015342831B2/en active Active
- 2015-11-06 CN CN201810698779.7A patent/CN108498495A/zh active Pending
- 2015-11-06 CA CA2967327A patent/CA2967327C/en active Active
- 2015-11-06 JP JP2017544552A patent/JP2017533969A/ja active Pending
- 2015-11-06 KR KR1020237036499A patent/KR20230152177A/ko active Pending
- 2015-11-06 KR KR1020177015227A patent/KR20170109527A/ko not_active Ceased
- 2015-11-06 BR BR112017009584A patent/BR112017009584A2/pt not_active Application Discontinuation
- 2015-11-06 WO PCT/US2015/059418 patent/WO2016073829A2/en not_active Ceased
- 2015-11-06 EP EP15857309.7A patent/EP3214934A4/en not_active Ceased
- 2015-11-06 US US15/523,665 patent/US12472157B2/en active Active
- 2015-11-06 KR KR1020227009489A patent/KR20220039853A/ko not_active Ceased
- 2015-11-06 RU RU2017119230A patent/RU2711913C2/ru active
- 2015-11-06 WO PCT/US2015/059589 patent/WO2016073931A1/en not_active Ceased
- 2015-11-06 EP EP21217485.8A patent/EP4000612A1/en active Pending
- 2015-11-06 US US15/524,636 patent/US20180296503A1/en not_active Abandoned
- 2015-11-06 CN CN201580072224.6A patent/CN107426997A/zh active Pending
-
2018
- 2018-09-20 HK HK18112150.1A patent/HK1252822A1/zh unknown
-
2019
- 2019-10-18 JP JP2019191044A patent/JP2020023549A/ja active Pending
- 2019-11-07 AU AU2019261762A patent/AU2019261762B2/en active Active
-
2021
- 2021-09-06 AU AU2021225263A patent/AU2021225263B2/en active Active
- 2021-09-10 JP JP2021147283A patent/JP2021193119A/ja active Pending
-
2023
- 2023-08-04 JP JP2023127716A patent/JP2023145734A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200436A patent/AU2024200436A1/en active Pending
-
2025
- 2025-07-30 JP JP2025126989A patent/JP2025160381A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020023549A5 (enExample) | ||
| JP2017533969A5 (enExample) | ||
| JP2023145734A5 (enExample) | ||
| CA2388609A1 (en) | Oxcarbazepine formulations for administration with or without food | |
| WO2006102446A3 (en) | Multi-particulate, modified-released colonic composition | |
| RU2017119230A (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
| RU2010147287A (ru) | Комбинированная композиция | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
| CA2240329A1 (en) | Improved delivery of multiple doses of medications | |
| IT1271495B (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
| JP2010525050A5 (enExample) | ||
| CA2588296A1 (en) | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease | |
| TW200630123A (en) | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form | |
| JP2012533565A5 (enExample) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2023109947A5 (enExample) | ||
| CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
| JP2005525329A5 (enExample) | ||
| WO2007038428A3 (en) | Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds | |
| HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
| JPWO2020146666A5 (enExample) | ||
| WO2005013935A3 (en) | Composition for releasing a weak base for an extended period of time | |
| FI4054582T3 (fi) | Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon |